1. Home
  2. EIC vs SLN Comparison

EIC vs SLN Comparison

Compare EIC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • SLN
  • Stock Information
  • Founded
  • EIC N/A
  • SLN 1994
  • Country
  • EIC United States
  • SLN United Kingdom
  • Employees
  • EIC N/A
  • SLN N/A
  • Industry
  • EIC Finance/Investors Services
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • EIC Finance
  • SLN Health Care
  • Exchange
  • EIC Nasdaq
  • SLN Nasdaq
  • Market Cap
  • EIC 334.1M
  • SLN 268.8M
  • IPO Year
  • EIC 2019
  • SLN N/A
  • Fundamental
  • Price
  • EIC $12.23
  • SLN $6.50
  • Analyst Decision
  • EIC
  • SLN Buy
  • Analyst Count
  • EIC 0
  • SLN 6
  • Target Price
  • EIC N/A
  • SLN $39.67
  • AVG Volume (30 Days)
  • EIC 136.8K
  • SLN 111.3K
  • Earning Date
  • EIC 11-13-2025
  • SLN 11-13-2025
  • Dividend Yield
  • EIC 12.78%
  • SLN N/A
  • EPS Growth
  • EIC N/A
  • SLN N/A
  • EPS
  • EIC 0.70
  • SLN N/A
  • Revenue
  • EIC $55,581,156.00
  • SLN $27,169,000.00
  • Revenue This Year
  • EIC $37.84
  • SLN N/A
  • Revenue Next Year
  • EIC $23.33
  • SLN N/A
  • P/E Ratio
  • EIC $17.54
  • SLN N/A
  • Revenue Growth
  • EIC 56.39
  • SLN 22.28
  • 52 Week Low
  • EIC $12.10
  • SLN $1.97
  • 52 Week High
  • EIC $16.71
  • SLN $18.73
  • Technical
  • Relative Strength Index (RSI)
  • EIC 28.50
  • SLN 67.27
  • Support Level
  • EIC $12.24
  • SLN $5.00
  • Resistance Level
  • EIC $13.40
  • SLN $5.83
  • Average True Range (ATR)
  • EIC 0.23
  • SLN 0.42
  • MACD
  • EIC -0.08
  • SLN 0.17
  • Stochastic Oscillator
  • EIC 10.42
  • SLN 82.38

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: